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Abstract. The bis(monosuccinimide) derivative of p,p'-bis(2-aminoethyl)-
diphenyl C60, 1, had substantial activity against HIV-1 and HIV-2 in
acutely or chronically infected human lymphocytes, and activity against
AZT-resistant HIV-1 in vitro (EC50 ~ 3-7 mM). This activity was primarily
associated with virucidal and anti-protease properties of 1. The fullerene
had very low cytotoxicity (IC50 > 100 mM in PBMC, H9, Vero, and CEM
cells) in various cells. Compound 1 did not interact with the CD4+ receptor
on human lymphocytes even at 100 mM. Similarly, no anti-fusion activity
was noted at that concentration. No toxicity in mice was apparent when 1
was administered intraperitoneally at 50 mg/kg per day for 6 days.
INTRODUCTION
While the physics and chemistry of fullerenes have expanded at a remarkable rate in the
last few years (1-3), the biology of this rapidly growing class of carbon clusters is in its
initial stages of development. The physiological attributes and potential medical
applications of fullerenes are limited in part by the fact that unfunctionalized fullerenes are
hydrophobic and insoluble in water. With the advent of methanofullerenes, fulleroids (4)
and other fullerene functionalization methodologies (5-15), several general approaches to
derivatized water-soluble fullerenes are now defined. Preliminary reports on the application
of a bis(monosuccinimide) derivative of p,p'-bis(2-aminoethyl)diphenyl C60, 1 (Figure 1) to
human immunodeficiency virus (HIV) have appeared (16-18). The concept for making
water soluble fullerenes was reduced to practice when we discovered that another cluster
class of compounds, namely polyoxometalates (POM), were found to inhibit HIV-1
protease (19). Since the size of certain POM fit the active site of this enzyme, we reasoned
that fullerenes, if they could be solubilized in biological medium, should also inhibit this
critical viral enzyme. At physiological pH, the terminal carboxylic acid groups of 1 are
deprotonated rendering the complex water soluble. We report here further information on
the antiviral activity, biochemical properties, antifusion/binding characteristics, and for the
first time, mammalian tolerance of this complex.
EXPERIMENTAL
Chemistry. The title complex, 1, was prepared and purified by the literature procedure
(16). All other reagents were reagent grade and used as received.
Figure 1. Structure of a bis(monosuccinimide) derivative of
p,p'-bis(2-aminoethyl)diphenyl C60 (1).
Virology and cytotoxicity. The cell culture assays and protocols were described
previously (16, 20, 21). For the inactivation studies with HIV-1LAI, 75 ml of virus
(approximately 200 TCID50) and 2 ml of compound 1 (5 to 25 mM) or medium without
drug (control) were incubated for 2 hr at 37°C in a Nalgene tube. After incubation, RPMI
1640 growth medium (3 ml) was added to each tube, then each was centrifuged at 40,000
rpm for 30 min at 4°C (Beckman 70.1Ti rotor). After removal of the supernatant, the virus
pellet was resuspended in fresh medium. The suspension was added to 10 ml of growth
medium containing 2 day phytohemagglutinin stimulated human peripheral blood mononu-
clear cells (PBMC) in 25 cm2 flasks. On day 6, the amount of virus in the supernatant was
quantitated by a reverse transcriptase (RT) assay and compared to untreated control (20).
Untreated virus infected control had a mean RT activity of 1,140 kdpm/ml.
Effect of fullerene on anti-CD4 antibody binding in CEM or PBMC cells. The
extent to which fullerene compounds will block the binding of anti-CD4 antibody in log
phase CEM cells or PBMC (unstimulated) was determined using a fluorescent activated
cell sorter (FACS). Cells (2 x 106) were incubated with 1 (1, 10, 25, 50 and 100 mM) in 10
ml RPMI-10% (or 20% for PBMC) inactivated fetal bovine serum for 3 hr at 37°C. The
POM HPA-23 (100 mM) was used as a positive control. Untreated control flasks were also
seeded (1 % DMSO and medium control). After incubation, the cells were centrifuged at
200 g for 10 min, washed with Dulbecco's phosphate buffered saline (PBS), and counted
with a hemacytometer to determine the viability by dye exclusion. The cell pellet was
resuspended in PBS (200 ml) and an aliquot (100 ml) was stained with mouse anti-CD3-
FITC/anti-CD4-PE antibody (20 ml) (Becton Dickinson, San Jose, CA) for 30 min at room
temperature in the dark. A negative control antibody (mouse anti-KLH-FITC/PE, Becton
Dickinson) was used to stain the remaining aliquot (100 ml). After incubation with
antibody, the cells were centrifuged at 200 g for 4 min, washed with PBS (500 ml),
recentrifuged for 10 min, resuspended in paraformaldehyde/PBS (1%, 500 ml) and stored at
4°C in the dark up to 72 hr prior to FACS analysis. FACS analysis was performed by
acquiring 5000 events on a Becton Dickinson FACSort and gating on intact cells
visualized by forward scatter versus ide scatter. Gated cells were analyzed by histogram to
obtain the red fluorescence (FL2) intensity mean channel number (MCN). Percent
inhibition of binding was determined as follows:
%I = 100(MCNmedium-MCNcompound)/ MCNmedium
Effect of fullerene on fusion of CEM and TF228.1.16 cells. Determination of the
extent to which fullerene compounds inhibit the formation of syncytia between CD4+ and
gp 120+ cell lines was performed using a modification of a previously reported technique
(22, 23). TF228.1.16 cells, obtained from SmithKline Beecham Pharmaceuticals (King of
Prussia, PA), are non-infectious cells derived from BJAB cells transfected with a vector
containing the full-length BH10 HIV-1 gp160. These cells stably express functionally
active gp120-gp41 on its surface and like virus infected cells release low level gp120 into
the media (23). CEM cells and TF228.1.16 cells (2.5 x 104 of each cell type) were mixed
or aliquoted separately into 96-well plates in 180 ml of HY medium (GIBCO, Grand
Island, NY) containing 10% heat inactivated fetal bovine serum. Compound 1 (1, 10, 50,
and 100 mM) was added in duplicate (20 ml/well). HPA-23 (1, 10, and 100 mM) was used
as a positive control. Negative untreated controls received only medium. Cells were
incubated for 16-18 hr in a 5% CO2 incubator at 37°C. Syncytia were counted in 5 fields
using 100x magnification.
Toxicity studies in mice. Random-bred Swiss CFW mice (female, 4 to 5 weeks old)
were obtained from Charles River Laboratory (Portage, MI). After acclimatization for 2
weeks, the mice were divided into 6 groups of 6 mice each and treated intraperitoneally
(i.p.) with compound 1 at a dose of 15, 30, and 50 mg/kg per day (mkd) for 6 days. Control
untreated, vehicle (2% DMSO) treated, and PBS treated groups were included. The
compound was dissolved in 2% DMSO/PBS and 0.5 ml was administered. Mice were
weighed individually on day 0, 1, 6, 8, 11, 15, and 22. Loss in weight, failure to gain
weight, and/or ruffled fur were considered signs of distress or toxicity.
RESULTS AND DISCUSSION
Compound 1 was evaluated for antiviral activity in acutely and chronically HIV infected
cells (Table 1). In human PBMC infected with HIV-1LAI, 1 demonstrated activity with a
median effective concentration (EC50 ± S.D.) value of 7.3 ± 5.9 mM  This water-soluble
methanofullerene was also found to be effective in chronically infected H9 cells with an
EC50 value of 10.8 ± 8.2 mM, and in acutely HIV-2ROD infected human PBMC with an
EC50 value of 5.5 ± 3.8 mM. 3'-Azido-3'-deoxythymidine (AZT) used as a positive control
had potent activity against HIV-1 and HIV-2 in acutely infected cells, but no effect in
chronically infected H9 cells (Table 1). When cell-free HIV-1 was incubated for 2 hr with
compound 1 (5-25 mM) and the virus was then concentrated and inoculated into fresh
mitogen stimulated human PBMC, virus infectivity was reduced by greater than 95%
relative to untreated control, suggesting virucidal activity. No cytotoxicity was demon-
strable with 1 in uninfected slowly dividing PBMC, and rapidly dividing H9, Vero or CEM
cells. With the exception of protease and TAT inhibitors, few compounds have
demonstrated selective antiviral activity in chronically infected cells (25).
The compound was also evaluated for its inhibitory effect on recombinant p66/51 HIV-1
reverse transcriptase (RT) using a poly(rA)n· ligo(T)12-18 as template-primer (24).
Compound 1 was active against this enzyme with a median inhibitory concentration (IC50)
of 4.6 mM. This value was of the same order of magnitude as that noted for the antiviral
assays (Table 1). However, the compound did not demonstrate selectivity since it also
inhibited cellular DNA polymerase a at a similar concentration. AZT-5'-triphosphate
(AZT-TP) and phosphonoformate (PFA), used as positive controls, were effective and
selective against HIV-1 RT.
Table 1. Summary of the effects of a water-soluble derivatized fullerene1 on HIV
production in acutely infected PBMC chronically infected H9 cells, its cytotoxicity in
uninfected PBMC, H9, Vero and CEM cells, and effect on viral and cellular polymerases.
Compound Antiviral activity (EC50, mM) in: Cytotoxicity (IC50, mM) in: Polymerases (IC50, mM):
PBMC a PBMCa H9b PBMC H9c Veroc CEMc HIV-1 RT DNA pol a
HIV-1LAI HIV-2ROD HIV-1IIIb
1 7.3 5.5 10.8 > 100d > 100> 100> 100 4.6 4.9
PFA 0.43 0.44 NDe > 640c ND > 100> 100 0.32 > 100
AZT 0.004 0.003 > 100 > 100c 60 23 13 0.04f > 100f
a Acutely infected cells. Virus yield was determined on day 6 after infection (20, 21). Values represent means
of quadruplicate experiments. The correlation coefficient for the data was > 0.96. Adapted from ref. 16.
bChronically infected cells. Virus yield was determined after 6 days of treatment. Values are mean of
duplicate experiments
c Measured by cell counts on day 6.
d Measured by radiolabeled thymidine uptake on day 2 and by cell counts on day 6.
e Not determined.
f AZT-TP was used for the enzyme assays (24).
Compound 1 was found to have an IC50 of 2.0 mM against recombinant HIV-1 protease.
The inhibition was time dependent and preincubation with the inhibitor resulted in greater
enzyme inhibition indicating a slow binding process (data not shown). The method used
for the assay was similar to that previously described (26). The collaborative group of
Friedman, Kenyon, and Wudl have also reported that 1 has activity against HIV-1 protease
with a Ki of 5.3 mM (17, 18).
Table 2. Effect of the fullerene 1 on anti-CD4 antibody binding in CEM cells.
Compound Class Concentration, mM % lnhibitiona
1 Fullerene 100 23.0
HPA-23 POM 100 83.8
aCells were stained with mouse anti-CD3-fluorescein isothiocyanate (FITC)/anti-CD4-phy-
coerythrin (PE) antibody. A negative control antibody [mouse anti-keyhole limpet
hemocyanin (KLH)-FITC/PE] was also used.
Since compound 1 is a charged molecule, it was important to determine if it interacted
with CD4+ receptor on lymphocytes. It appears that 1 demonstrated a modest ability (23%
at 100 mM) to block the binding of anti-CD4 antibody to CD4+ CEM cells (Table 2). The
compound was similarly evaluated in PBMC up to 100 mM; no appreciable inhibition
(1.1%) was noted (data not shown). In a cell fusion assay between CEM and TF228.1.16
cells, compound 1 had no activity up to a concentration of 100 mM, whereas HPA-23 used
as a positive control completely inhibited fusion at 1 mM. T ken together, these data
suggest that 1 does not interact with either the viral glycoprotein gp120 nor with the
cellular receptor CD4+. However, these results do not rule out the possibility that other
related fullerenes could have a different inhibitory profile.
The development of single agents to treat HIV-1 infections inevitably results in the
development of drug-resistant virus (25, 28). The availability of AZT-resistant and
susceptible viruses allowed us to evaluate the compounds for their susceptibility to these
viruses in acutely infected PBMC. The susceptibility of the pretherapy isolate compared to
post-therapy AZT-resistant virus in lymphocytes was not substantially different (Table 3).
With the nevirapine (BI-RG587)-resistant and sensitive HIV-1 (27), the EC50 increased
from 0.53 mM to 8.7 mM, respectively, a 16-fold increase in resistance. In the same assay,
the EC50 value for the non-nucleoside RT inhibitor TIBO R82150 increased 506-fold (data
not shown). The lack of cross-resistance with AZT suggests that combination studies of
the fullerenes with AZT should be considered in vit o (29).
Table 3. Effects of a derivatized fullerene, 1, against a pair of AZT-sensitive and resistant
HIV-1 in acutely infected primary human lymphocytes.
CompoundAZT-susceptible HIV-1H1 2-2 AZT-resistant HIV-1G910-6 Fold increase
EC50, mM EC50, mM in EC50 value
1 2.8 2.7 1.0
AZT £ 0.001 0.18 ³ 180
Because of concerns related to the potential carcinogenic effects of benzene and related
compounds, Nelson et al. (30) were the first to study the effect of topical fullerenes in
mammals. They demonstrated a lack of carcinogenic effects of C60 and C70 after acute and
subchronic topical applications to mice. Since no systemic toxicity studies have been
reported with any fullerene, we evaluated the intraperitoneal toxicity of compound 1 in
mice treated daily for 6 days at 15, 30 and 50 mkd. A slight decline in weight was noted
after the first dose in all the control and treated groups except for the untreated control
group (Figure 2). Subsequently, all the animals gained weight over the period of
observation and no animal died in any of the groups. There was no statistically significant
difference in the weights of the treated groups versus control groups (p > 0.05). These
results indicate that 1 was well tolerated up to a dose of 50 mkd (qd x 6d). The animals in
this experiment continue to be monitored. As of 2 months after the initial treatment, none
of the animals have died. Pharmacokinetic studies in rats with this compound are currently
being performed and the results will be reported elsewhere.
Figure 2. Effect of the water-soluble fullerene 1 in Swiss mice.
In summary, we have demonstrated for the first time that a water-soluble fullerene has
potent and selective activity against HIV-1 in acutely and chronically infected cells.
Compound 1 was also shown to have virucidal properties suggesting direct interactions
between the fullerene and HIV-1. Although additional studies on the mechanism of
antiviral action of this compound are warranted, results suggest that the compound can
inhibit HIV-1 RT and protease. However, 1 had no significant antifusion properties and it
did not interact with the CD4+ receptor on lymphocytes (Tables 1 and 2). Of significance
was the recent report that a fullerene carboxylic acid had photochemical properties and
induced DNA cleavage predominantly at guanine residues (9). The single strand breaks
were presumably generated by singlet oxygen. This physicochemical property could
account in part for the virucidal property of 1. The search for compounds that inactivate
HIV in genital secretion without spermicidal properties or toxicity is a desirable medical
goal. Such a compound may also have utility in inactivating HIV in blood and blood
products (31). Compound 1 can be considered as a lead in the discovery of other fullerenes
with greater virucidal activity. It is also encouraging that this class of compound is
essentially non-toxic in vitro and is well tolerated in small mammals at high doses.
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